

SPARC/Sec/SE/2018-19/062

15<sup>th</sup> February 2019

To  
**The National Stock Exchange of India Ltd.**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

**BSE Limited**  
P J Towers,  
Dalal street,  
Mumbai - 400001

**Ref:** Scrip Code: NSE: SPARC; BSE: 532872

**Sub:** Return of Product Rights by partner for ELEPSIA™ XR 1000/1500 mg

Dear Sir/Madam,

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform that we have received a communication from Sun Pharma Global FZE (SPGFZE), a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, informing us that SPGFZE is not planning to launch Elepsia™ XR (Levetiracetam Extended-Release Tablets) as CNS is not its focussed therapeutic area in US market, and therefore SPGFZE has decided to return the product rights back to SPARC.

SPARC had out-licensed ELEPSIA™ XR to SPGFZE in July 2016; and was eligible for sales linked milestone and royalties upon commercialization of Elepsia™ XR.

Consequently, SPARC would find another partner for commercialising the captioned product.

We request you to kindly take the same on record.

Yours faithfully,  
For **Sun Pharma Advanced Research Company Limited**

A handwritten signature in black ink, appearing to read "Debashis Dey".

**Debashis Dey**  
Company Secretary